Spero Therapeutics Chief Legal Officer Tamara Joseph to depart March 6, 2024

Spero Therapeutics, Inc.

Tamara Joseph, Chief Legal Officer and Corporate Secretary, is leaving effective March 6, 2024 to pursue other interests.
Severance includes continuation of base salary for nine months totaling $356,298.75, plus prorated cash bonus of $34,266.98.
Joseph will provide consulting services on an hourly as-needed basis for nine months at $395/hour; stock options and RSUs continue vesting.
Separation and Consulting Agreement entered February 9, 2024; full terms to be filed with Form 10-K.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Tamara Joseph

Chief Legal Officer and Corporate Secretary

SPRO · Spero Therapeutics, Inc.

Effective: 2024-03-06
Filed: February 9, 2024, 6:59 PM ET

Tamara Joseph, the Chief Legal Officer and Corporate Secretary of Spero Therapeutics, Inc. (the “Company”), is stepping down from that position to pursue other interests, effective as of March 6, 2024 (the “Effective Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Tamara Joseph departed as Chief Legal Officer and Corporate Secretary at Spero Therapeutics, Inc..

Action: stepping down
Role: Chief Legal Officer and Corporate Secretary

Exact text from the filing

Tamara Joseph, the Chief Legal Officer and Corporate Secretary of Spero Therapeutics, Inc. (the “Company”), is stepping down from that position to pursue other interests, effective as of March 6, 2024 (the “Effective Date”).

View on SEC.gov

Spero Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-029913

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.